Skip to main content
. Author manuscript; available in PMC: 2015 Aug 12.
Published in final edited form as: Mol Cancer Ther. 2015 Feb 23;14(3):769–778. doi: 10.1158/1535-7163.MCT-14-0926

Figure 2.

Figure 2

Enzalutamide decreases proliferation and anchorage-independent growth and increases apoptosis in multiple TNBC molecular subtypes. A, crystal violet assay of TNBC cell lines treated with vehicle control (Veh), enzalutamide (ENZ), and/or DHT in 5% charcoal-stripped serum for 5 to 10 days. B, apoptotic index of nuclear red SUM159PT, HCC1806 and BT549 cell lines treated with Veh (open circle) or enzalutamide (solid square) and green fluorescent caspase-3/7 reagent and imaged on the Incucyte ZOOM (Essen BioSciences). C, soft agar assays of TNBC cell lines treated with Veh or enzalutamide in full serum, stained with nitro blue tetrazolium, and quantified using pixel contrast analysis.*, P < 0.05; **, P < 0.01; ***, P < 0.001; error bars, SD.